MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ekir.2020.01.006

Медицинская библиотека · Kidney international reports · 2020

Randomized Controlled Trial of Difelikefalin for Chronic Pruritus in Hemodialysis Patients.

Fishbane Steven, Mathur Vandana, Germain Michael J, Shirazian Shayan, Bhaduri Sarbani, Munera Catherine, Spencer Robert H, Menzaghi Frédérique, Trial Investigators

СтатьяПеревод в очереди

Аннотация

INTRODUCTION

There is an unmet medical need for pruritus associated with chronic kidney disease, a distressing complication characterized by generalized and persistent itch affecting 20% to 40% of patients undergoing hemodialysis. Here we report the results of a phase 2 trial evaluating the efficacy and safety of a novel peripherally restricted kappa opioid receptor agonist, difelikefalin, in adult patients undergoing hemodialysis with pruritus.

METHODS

In this study, 174 hemodialysis patients with moderate-to-severe pruritus were randomly assigned to receive difelikefalin (0.5, 1.0, or 1.5 μg/kg) or placebo intravenously thrice weekly after each hemodialysis session for 8 weeks in a double-blind, controlled trial. The primary endpoint was the change from baseline at week 8 in the weekly mean of the 24-hour Worst Itching Intensity Numerical Rating Scale score. The secondary efficacy endpoint was the change in itch-related quality of life measured by the Skindex-10 questionnaire. Other endpoints included safety, sleep quality, and additional measures including the 5-D itch scale.

RESULTS

A significant reduction from baseline in itch intensity scores at week 8 favored all difelikefalin doses combined versus placebo (P = 0.002). Difelikefalin also showed improvement over placebo in Skindex-10, 5-D itch, and sleep disturbance scores (P ≤ 0.005). Overall, 78% of patients receiving difelikefalin reported treatment-emergent adverse events versus 42% of patients given placebo, with diarrhea, dizziness, nausea, somnolence, and fall being the most frequent (≥5%).

CONCLUSION

In this trial, difelikefalin effectively reduced itching intensity and improved sleep and itch-related quality of life.

Для цитирования: Fishbane Steven, Mathur Vandana, Germain Michael J, Shirazian Shayan, Bhaduri Sarbani, Munera Catherine, Spencer Robert H, Menzaghi Frédérique, Trial Investigators. Randomized Controlled Trial of Difelikefalin for Chronic Pruritus in Hemodialysis Patients.. Kidney international reports. 2020. DOI: 10.1016/j.ekir.2020.01.006.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.